30 C
July 24, 2024
The Hona News

Potent and highly selective CDK9 inhibitor for treatment of hematologic malignancies

To evade cell cycle controls, malignant cells rely upon rapid expression of select proteins to mitigate pro-apoptotic signals resulting from damage caused by both cancer treatments and unchecked over-proliferation. Cyclin-dependent kinase 9 (CDK9)-dependent signaling induces transcription of downstream oncogenes promoting tumor growth, especially in hyperproliferative “oncogene-addicted” cancers, such as human hematological malignancies (HHMs).

Source link

Related posts

Research reveals promising approach to enhance treatment for sleep apnea-related issues


Nano-immunotherapy developed to improve lung cancer treatment


Decline in global adolescent fertility rates is counteracted by increasing teen births in Sub-Saharan Africa: Study


Leave a Comment